- May 16, 2017 09:27 (CEST)Regulatory
- May 15, 2017 15:50 (CEST)
Since 2016, Cyxone AB and Swiss pharmaceutical manufacturer Bachem AG have worked closely on the production of syntheses of Cyxone's development substance T20K, and on the production of substances for studies that started last year.
Cyxone's development substance T20K's capacity to prevent and inhibit multiple sclerosis in animal models now verified by independent studyMarch 10, 2017 13:00 (CET)Regulatory
- December 21, 2016 14:00 (CET)Regulatory
Today, Cyxone announce that they will acquire the entire family of patents protecting the Company's main candidate T20K, from the Medical University of Vienna. The cost of € 100,930 includes VAT and corresponds to the costs of the patenting process.
- December 19, 2016 09:35 (CET)Regulatory
Cyxone announce that T20K demonstrates no measurable toxic effect in mice after oral administration of up to 100 mg/kg in a single dose. Even at an oral dose of 250 mg/kg, half of the animals recovered well after treatment. Low toxicity of injected T20K has previously been reported by Cyxone.
- November 21, 2016 09:02 (CET)Regulatory
- September 19, 2016 14:45 (CEST)Regulatory
- August 31, 2016 16:43 (CEST)Regulatory
Cyxone has completed its first toxicity study of drug candidate T20K for the treatment of Multiple Sclerosis (MS) through the LPT Laboratory of Pharmacology and Toxicology GmbH in Germany.